Search
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigationalwith Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022. … [L44396] On July 21, 2023, maralixibat was also approved by Health Canada.[L47541]
Fenofibric acid
go.drugbank.com/drugs/DB13873ApprovedInvestigationalFenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. … [A32038,L12855] Due to its high hydrophilicity and poor absorption profile,[A32038] prodrug ,[fenofibrate], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed
Flutemetamol (18F)
go.drugbank.com/drugs/DB09151ApprovedInvestigationalIt is used to evaluate Alzheimer's disease (AD) or other causes of cognitive decline as an Aβ-specific positron emission tomography (PET) ligand.[L35029] … Flutemetamol (18F), an analogue of [(11)C]PIB,[A18519] is a radioactive diagnostic drug used for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density.
Categories: Compounds used in a research, industrial, or household settingAtracurium besylate
go.drugbank.com/drugs/DB00732ApprovedIts lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents
Zalifrelimab
go.drugbank.com/drugs/DB15632InvestigationalZalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently or in Combination With Anti-ctla-4 in Second-line Cervical Cancer).
Oxytocin
go.drugbank.com/drugs/DB00107ApprovedInvestigationalVet approved[A229008,A228593] In the mid-1950s, synthetic oxytocin was successfully synthesized by a biochemist named Vincent du Vigneaud; he was later recognized with a Nobel prize for his work. … [A229113] Although most commonly linked to labor and delivery, oxytocin actually has broad peripheral and central effects.
Efanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigational[A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414] … [A257464] Efanesoctocog alfa was designed to have an extended half-life, and to surpass the half-life ceiling to which other forms of recombinant FVIII are subjected due to their association with von Willebrand
Ticagrelor
go.drugbank.com/drugs/DB08816ApprovedInvestigational[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010. … [L14207] Ticagrelor was granted FDA approval on 20 July 2011.[L14201]
Boceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnwith [DB00811], [DB00008], and [DB00022] as first line therapy for Hepatitis C [A19593]. … Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Etomidate
go.drugbank.com/drugs/DB00292ApprovedInvestigationalImidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.
Products: ETOMIDATE-LIPURO 20MG/10ML INJ IN 10ML GA